Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Portales, F. [1 ]
Philip, P. A. [2 ]
Hammel, P. [3 ]
Buscaglia, M. [4 ]
Pazo-Cid, R. [5 ]
Manzano Mozo, J. L. [6 ]
Kim, E. S. [7 ]
Dowden, S. [8 ]
Zakari, A. [9 ]
Borg, C. [10 ]
Terrebonne, E. [11 ]
Rivera Herrero, F. [12 ]
Li, J. Shiansong [13 ]
Ong, T. J. [14 ]
Nydam, T. [14 ]
Lacy, J. [15 ]
机构：
[1] Inst Reg Canc Montpellier ICM, Digestif, Montpellier, France
[2] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[3] Hop Beaujon, Gastroenterol, Clichy, France
[4] Azienda Osped Univ San Martino, Med Oncol, Genoa, Italy
[5] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain
[6] Hosp Badalona Germans Trias & Pujol, Med Oncol, Barcelona, Spain
[7] Levine Canc Inst, Med Oncol, Charlotte, NC USA
[8] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[9] Florida Hosp Canc Inst, Gastro Intestinal Canc Program, Orlando, FL USA
[10] Ctr Hosp Belfort Montbeliard, Med Oncol, Montbeliard, France
[11] Hosp Haut Leveque, Med Oncol, Giround, France
[12] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[13] Celgene Corp, Biostat, Summit, NJ USA
[14] Celgene Corp USA, Med Affairs, Summit, NJ USA
[15] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
730P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] nab-paclitaxel (nab-P) plus carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim quality of life (QoL) outcomes from the phase 3 ABOUND. sqm study
    Thomas, M.
    Aix, S. Ponce
    Ko, A.
    Jotte, R.
    Ong, T. J.
    Page, R.
    Socinski, M.
    Trunova, N.
    Villaflor, V.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
    Safran, Howard
    Perez, Kimberly
    Charpentier, Kevin
    Austin, Trevor Clark
    Mantripragada, Kalyan C.
    Bishop, Kenneth D.
    Lombardo, Alise
    Houlihan, Lindsay
    Mitchell, Kristen
    Rosati, Kayla
    Martel, Diane
    Shaw, Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).
    Lowery, Maeve Aine
    Capanu, Marinela
    Glassman, Danielle C.
    Covington, Christina M.
    Gluskin, Jill
    Brenner, Robin
    Li, Chien-Feng
    Bomalaski, John S.
    Johnston, Amanda
    Barba, Adalberto
    Yu, Kenneth H.
    Kelsen, David Paul
    Abou-Alfa, Ghassan K.
    Saltz, Leonard
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [45] Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer.
    Chiorean, E. Gabriela
    Wan, Yin
    Whiting, Scott
    Kayitalire, Louis
    Botteman, Marc
    Ji, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [47] Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study.
    Kunzmann, Volker
    Hartlapp, Ingo
    Scheurlen, Michael
    Einsele, Hermann
    Mueller, Justus
    Kenn, Werner
    Steger, Ulrich
    Germer, Christoph T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem)
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Diana, A.
    Troiani, T.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [49] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [50] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
    Wainberg, Zev A.
    Hochster, Howard S.
    George, Ben
    Gutierrez, Martin
    Johns, Mark Emery
    Chiorean, E. Gabriela
    Kwak, Eunice Lee
    Kalyan, Aparna
    Manax, Victoria
    Ye, Moncy
    Chen, Tianlei
    Trunova, Nataliya
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345